CTLA-4 blockade with ipilimumab and other Abs has been reported to impede tumors through various mechanisms, primarily by favoring CD28 binding to CD80/86, especially in tumor-draining lymph nodes where APCs cross-present tumor antigens to activate tumor-reactive T-cells. Here, CD28 is linked to neoplasm.